Beam Therapeutics Inc. (BEAM) stock
BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/304% below fair value
$22.83−1.20 (-4.99%)
Close on Nov 13, 2026Market cap $2.36BP/E –Yield –
Beam Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Beam Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -54.7%. For fiscal 2025 it was -57.2%, against -593.1% the year before. The highest annual figure on record is -35.1% in fiscal 2023.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -57.2% | +535.9 |
| FY2024 | Dec 31, 2024 | -593.1% | −558.0 |
| FY2023 | Dec 31, 2023 | -35.1% | +439.5 |
| FY2022 | Dec 31, 2022 | -474.5% | +240.4 |
| FY2021 | Dec 31, 2021 | -714.9% | +810085.1 |
| FY2020 | Dec 31, 2020 | -810800.0% | −375655.6 |
| FY2019 | Dec 31, 2019 | -435144.4% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -25036.3% | −23829.9 |
| Q1 FY2026 | Mar 31, 2026 | -297.2% | +1153.0 |
| Q4 FY2025 | Dec 31, 2025 | 214.1% | +514.6 |
| Q3 FY2025 | Sep 30, 2025 | -1162.4% | −484.9 |
| Q2 FY2025 | Jun 30, 2025 | -1206.4% | −433.0 |
| Q1 FY2025 | Mar 31, 2025 | -1450.2% | −118.6 |
| Q4 FY2024 | Dec 31, 2024 | -300.5% | −345.7 |
| Q3 FY2024 | Sep 30, 2024 | -677.5% | −118.6 |
| Q2 FY2024 | Jun 30, 2024 | -773.5% | −362.0 |
| Q1 FY2024 | Mar 31, 2024 | -1331.6% | −933.1 |
| Q4 FY2023 | Dec 31, 2023 | 45.2% | +236.6 |
| Q3 FY2023 | Sep 30, 2023 | -558.9% | +134.7 |
| Q2 FY2023 | Jun 30, 2023 | -411.5% | +20.6 |
| Q1 FY2023 | Mar 31, 2023 | -398.5% | +422.4 |
| Q4 FY2022 | Dec 31, 2022 | -191.4% | −64.7 |
| Q3 FY2022 | Sep 30, 2022 | -693.6% | +2991.6 |
| Q2 FY2022 | Jun 30, 2022 | -432.1% | +1270451.3 |
| Q1 FY2022 | Mar 31, 2022 | -820.8% | +3358512.5 |
| Q4 FY2021 | Dec 31, 2021 | -126.7% | +1590940.0 |
| Q3 FY2021 | Sep 30, 2021 | -3685.2% | +570514.8 |
| Q2 FY2021 | Jun 30, 2021 | -1270883.3% | −700583.3 |
| Q1 FY2021 | Mar 31, 2021 | -3359333.3% | −2851700.0 |
| Q4 FY2020 | Dec 31, 2020 | -1591066.7% | −1126900.0 |
| Q3 FY2020 | Sep 30, 2020 | -574200.0% | −257450.0 |
| Q2 FY2020 | Jun 30, 2020 | -570300.0% | −272616.7 |
| Q1 FY2020 | Mar 31, 2020 | -507633.3% | – |
| Q4 FY2019 | Dec 31, 2019 | -464166.7% | – |
| Q3 FY2019 | Sep 30, 2019 | -316750.0% | – |
| Q2 FY2019 | Jun 30, 2019 | -297683.3% | – |
See a number that looks wrong?